CR20210410A - Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer - Google Patents
Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncerInfo
- Publication number
- CR20210410A CR20210410A CR20210410A CR20210410A CR20210410A CR 20210410 A CR20210410 A CR 20210410A CR 20210410 A CR20210410 A CR 20210410A CR 20210410 A CR20210410 A CR 20210410A CR 20210410 A CR20210410 A CR 20210410A
- Authority
- CR
- Costa Rica
- Prior art keywords
- mat2a
- methods
- aza
- treating cancer
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente descripción proporciona compuestos de acuerdo a la Fórmula I y sus sales, tautómeros y/o isotopólogos farmacéuticamente aceptables como se describe en la descripción. Los compuestos son inhibidores de la isoforma 2A de metionina adenosiltransferasa (MAT2A). También se proporcionan composiciones farmacéuticas y métodos para usar los compuestos para tratar cánceres, lo que incluye algunos cánceres en los que se elimina el gen que codifica la metiltioadenosina fosforilasa (MTAP).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785519P | 2018-12-27 | 2018-12-27 | |
PCT/US2019/068652 WO2020139991A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210410A true CR20210410A (es) | 2021-12-08 |
Family
ID=69400625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210410A CR20210410A (es) | 2018-12-27 | 2019-12-27 | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer |
Country Status (35)
Country | Link |
---|---|
US (1) | US20220144820A1 (es) |
EP (1) | EP3902803B1 (es) |
JP (2) | JP7418441B2 (es) |
KR (1) | KR20220051301A (es) |
CN (1) | CN113454085B (es) |
AR (1) | AR117544A1 (es) |
AU (1) | AU2019416349B2 (es) |
BR (1) | BR112021012595A2 (es) |
CA (1) | CA3124952A1 (es) |
CL (1) | CL2021001721A1 (es) |
CO (1) | CO2021009879A2 (es) |
CR (1) | CR20210410A (es) |
DK (1) | DK3902803T3 (es) |
EA (1) | EA202191801A1 (es) |
ES (1) | ES2942310T3 (es) |
FI (1) | FI3902803T3 (es) |
GE (1) | GEP20237519B (es) |
HR (1) | HRP20230161T1 (es) |
HU (1) | HUE061834T2 (es) |
IL (1) | IL284326B1 (es) |
JO (1) | JOP20210172A1 (es) |
LT (1) | LT3902803T (es) |
MA (1) | MA54608B1 (es) |
MD (1) | MD3902803T2 (es) |
MX (1) | MX2021007829A (es) |
PE (1) | PE20212090A1 (es) |
PL (1) | PL3902803T3 (es) |
PT (1) | PT3902803T (es) |
RS (1) | RS64135B1 (es) |
SG (1) | SG11202106637SA (es) |
SI (1) | SI3902803T1 (es) |
TW (1) | TWI816962B (es) |
UA (1) | UA127525C2 (es) |
WO (1) | WO2020139991A1 (es) |
ZA (1) | ZA202104423B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
US20220106276A1 (en) | 2018-12-10 | 2022-04-07 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
EP4188920A1 (en) | 2020-07-31 | 2023-06-07 | Tango Therapeutics, Inc. | Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers |
CN115960098A (zh) * | 2020-09-11 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
WO2022206730A1 (zh) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
WO2022253242A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
KR20240089791A (ko) | 2021-10-20 | 2024-06-20 | 인실리코 메디신 아이피 리미티드 | 메티오닌 아데노실트랜스퍼라제 2a (mat2a) 억제제 및 그의 용도 |
US20230192679A1 (en) * | 2021-12-17 | 2023-06-22 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
WO2023116696A1 (zh) * | 2021-12-21 | 2023-06-29 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
WO2023169554A1 (zh) * | 2022-03-11 | 2023-09-14 | 赛诺哈勃药业(成都)有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
TW202415370A (zh) | 2022-10-13 | 2024-04-16 | 南韓商韓美藥品股份有限公司 | 新穎三環衍生物化合物以及其應用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
HUP0302173A2 (hu) | 2000-09-15 | 2003-09-29 | Vertex Pharmaceuticals Incorporated | Protein kináz inhibitorokként alkalmazható pirazolvegyületek |
SG11201901747VA (en) * | 2016-08-31 | 2019-03-28 | Agios Pharmaceuticals Inc | Inhibitors of cellular metabolic processes |
IL270727B2 (en) | 2017-05-22 | 2023-03-01 | Janssen Pharmaceuticals Inc | Transduced indulin derivatives as inhibitors of dengue virus replication |
BR112020020104A2 (pt) * | 2018-03-30 | 2021-01-26 | Agios Pharmaceuticals, Inc. | inibidores heterobicíclicos de mat2a e métodos de uso para o tratamento de câncer |
PE20212303A1 (es) * | 2018-12-27 | 2021-12-10 | Les Laboratoires Servier Sas | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer |
BR112021023825A2 (pt) * | 2019-05-31 | 2022-02-08 | Servier Lab | Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer |
-
2019
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/en active Active
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 US US17/418,442 patent/US20220144820A1/en active Pending
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 BR BR112021012595-7A patent/BR112021012595A2/pt unknown
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/en active Application Filing
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 CN CN201980092742.2A patent/CN113454085B/zh active Active
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 CA CA3124952A patent/CA3124952A1/en active Pending
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 KR KR1020217023828A patent/KR20220051301A/ko unknown
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 JO JOP/2021/0172A patent/JOP20210172A1/ar unknown
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
- 2019-12-27 IL IL284326A patent/IL284326B1/en unknown
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
-
2021
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210317A1 (ar) | مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان | |
CR20210409A (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
ZA202104423B (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
PH12020551507A1 (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
PH12021551274A1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors | |
PH12021550995A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
MX2022014648A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. | |
JOP20200342A1 (ar) | مشتقات بيرازين مدمجة كمثبطات a2a/a2b | |
PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
MX2020012376A (es) | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. | |
MX2023004518A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
MX2022002219A (es) | Triazolopirimidinas como inhibidores de a2a/a2b. | |
MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
MX2023004802A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |